Although tumour growth was significantly reduced, the tumour mass did still increase over the duration of the experiment; however, the results from this and previous research suggest the true potential of the PBOX compounds in vivo could lie in their combination with other anticancer compounds, recent data have shown the ability of the PBOXs to synergise with other compounds including imatinib and the CDK1 inhibitor flavopiridol. Here, CDK1 is linked to neoplasm.